Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 03, 2023 10:30 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference

Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will...
October 27, 2022 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Receives FDA Fast Track Designation for Radionuclide Therapy Candidate ITM-11 (n.c.a. 177Lu-edotreotide) in Neuroendocrine Tumors (GEP-NETs)

Garching / Munich, October 27, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) has...
October 24, 2022 02:30 ET | Source: ITM Isotope Technologies Munich SE

ITM: Isotope Production System Begins Commercial Production of Cancer-Fighting Lutetium-177

ONTARIO, CANADA, and MUNICH, GERMANY, October 24, 2022 – An international collaboration between Bruce Power, Isogen (a Kinectrics and Framatome company) and ITM Isotope Technologies Munich SE (ITM),...
October 19, 2022 08:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors

Exclusive license from Helmholtz Munich will enable ITM to access IP and know-how to develop and commercialize ITM-31 for glioblastoma patients Garching/Munich, Germany, October 19, 2022 – ITM...
October 13, 2022 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Multiplies Production Capacity for its n.c.a. Lutetium-177

Garching / Munich, Germany – October 13, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the successful completion of a new production...
September 08, 2022 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and BAMF Health Enter Global Cooperation Agreement for Targeted Radiopharmaceuticals in U.S. Radiopharmacy and Clinic Network

Garching / Munich, Germany, and Grand Rapids, MI, U.S., September 08, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and BAMF (Bold Advanced Medical...
September 06, 2022 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present Trial Design of Ongoing Phase III COMPOSE Study in Advanced Neuroendocrine Tumors at ESMO 2022

Garching / Munich, September 6, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that a scientific poster on the design of its second...
August 18, 2022 05:18 ET | Source: ITM Isotope Technologies Munich SE

ITM Acquires a New Platform for the Development of Next-Generation Theranostics

• Technology platform for PET tracers strengthens ITM’s radiodiagnostic portfolio • Additional assets potentially expand ITM’s pipeline of novel targeted radionuclide therapeutics Garching /...
July 22, 2022 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Dr. Sebastian Marx as Chief Business Officer and Member of Executive Board

Garching / Munich, July 22, 2022 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Sebastian Marx to its Executive Board...
July 21, 2022 05:21 ET | Source: ITM Isotope Technologies Munich SE

ITM Signs Clinical Supply Agreement with Y-mAbs for n.c.a. Lutetium-177

ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA Complex for GD2-positive...